You are here

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Last updated on July 6, 2018

FOR MORE INFORMATION
Study Location
UC San Diego Moores Cancer Center
La Jolla, California, 92037-0845 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable
disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously
irradiated. Availability of tumor specimen taken within 1 year prior to study entry,
with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed.
Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy
or for which no standard therapy is available, and Phase 2, patients with NSCLC,
melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC
must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1
translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with
advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard
therapy or for which no standard therapy is available, and Phase 2, patients with
NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic
disease setting allowed. Activating EGFR mutation, ALK, ROS1
translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN,
NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior
therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either
inoperable or requires extensive resection. Prior treatment with agents targeting
CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1
translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN,
bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements
are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease
setting allowed.

- ECOG performance status 0 or 1

- Estimated life expectancy of at least 3 months

- Adequate bone marrow, renal, and liver function

- Resolved acute effects of prior therapy

- Negative serum pregnancy test at screening

- Male and female patients able to have children must agree to use 2 highly effective
methods of contraception throughout the study and for at least 60 days after last dose

- Signed and dated informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or
small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14
days prior to study entry.

- Current or prior use of immunosuppressive medication within 7 days prior to study
entry

- Active autoimmune disease requiring systemic steroids or immunosuppressive agents
within 7 days prior to study entry

- Known prior or suspected hypersensitivity to investigational products

- Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry

- Patients with known symptomatic brain metastases requiring steroids

- Previous high-dose chemotherapy requiring stem cell rescue

- Prior allogeneic stem cell transplant or organ graft

- Any of the following within 6 months prior to study entry: myocardial infarction,
uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
heart failure, cerebrovascular accident, or transient ischemic attack

- Symptomatic pulmonary embolism within 6 months prior to study entry

- Known HIV or AIDS-related illness

- Active infection requiring systemic therapy

- Positive HBV or HCV test indicating acute or chronic infection

- Administration of a live vaccine within 4 weeks prior to study entry

- Diagnosis of other malignancy within 5 years, except for adequately treated basal cell
or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or
low-grade (Gleason ?6) prostate cancer

- Participation in other studies involving investigational drug(s) within 4 weeks prior
to study entry and/or during study participation

- Persisting toxicity related to prior therapy >Grade 1

- Other severe acute or chronic medical condition

- Combo C :Existing periorbital edema.

- Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture
(within 12 weeks prior study entry)

NCT02554812
Pfizer
Recruiting
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Renal Cell Cancer
NCT02684006
All Genders
18+
Years
Multiple Sites
Non-Small Cell Lung Cancer
NCT02349633
All Genders
18+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune modulators into this study is based on preclinical and clinical data supportive of single-agent tolerability and potential clinical benefit, as well as non-clinical data suggesting safety, tolerability and clinical benefit of the agent(s) in combination with avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as follows:

  • Combination A: avelumab plus utomilumab (4-1BB agonist mAb)
  • Combination B: avelumab plus PF-04518600 (OX40 agonist mAb)
  • Combination C: avelumab plus PD 0360324 (M-CSF mAb)
  • Combination D: avelumab plus utomilumab plus PF-04518600 Each combination will be studied individually in 2 study parts: 1) a Phase 1b Lead-in part to evaluate safety, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and RP2D (if applicable), of the combination, and 2) a Phase 2 part to evaluate efficacy and further evaluate safety of the selected dose from the Phase 1b portion in pre-specified patient populations.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Advanced Cancer
  • Drug: Avelumab
    Anti-PD-L1 antibody given until disease progression.
    Other Name: MSB0010718C
  • Drug: Utomilumab
    Anti-4-1BB antibody at 1 of 3 dose levels to optimize the combination with avelumab. Treatment with the combination of avelumab and PF-05082566 will continue until disease progression.
    Other Name: PF-05082566
  • Drug: PF-04518600
    PF-04518600 will be administered at increasing dose levels in combination with avelumab.
  • Drug: PD 0360324
    PD 0360324 will be administered at increasing dose levels in combination with avelumab.
  • Experimental: Cohort A1
    NSCLC patients treated with avelumab + utomilumab (Dose level 1)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A2
    NSCLC patients treated with avelumab + utomilumab (Dose level 2)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A3
    NSCLC patients treated with avelumab + utomilumab (Dose level 3)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A4
    Melanoma patients treated with avelumab +utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A5
    SCCHN patients treated with avelumab + utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A6
    TNBC patients treated with avelumab + utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A7
    SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A8
    NSCLC first-line Stage IV treated with avelumab +PF-05082566
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Combination B Dose Escalation
    PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PF-04518600
  • Experimental: Combination B Expansion Cohorts
    PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PF-04518600
  • Experimental: Combination C Dose escalation cohorts
    PD 0360324 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PD 0360324
  • Experimental: Combination C Dose expansion cohorts
    PD 0360324 + aveluamb in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: PD 0360324
  • Experimental: Combination D Dose escalation cohorts
    PF-05082566 + PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
    • Drug: PF-04518600
  • Experimental: Combination D Dose expansion cohorts
    PF-05082566 + PF-04518600 + avelumab in selected tumor types
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
    • Drug: PF-04518600
  • Experimental: Cohort A9
    NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
  • Experimental: Cohort A10
    NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
    Interventions:
    • Drug: Avelumab
    • Drug: Utomilumab
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
560
February 21, 2020
December 10, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed.
  • ECOG performance status 0 or 1
  • Estimated life expectancy of at least 3 months
  • Adequate bone marrow, renal, and liver function
  • Resolved acute effects of prior therapy
  • Negative serum pregnancy test at screening
  • Male and female patients able to have children must agree to use 2 highly effective methods of contraception throughout the study and for at least 60 days after last dose
  • Signed and dated informed consent

Exclusion Criteria:

  • Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14 days prior to study entry.
  • Current or prior use of immunosuppressive medication within 7 days prior to study entry
  • Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
  • Known prior or suspected hypersensitivity to investigational products
  • Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
  • Patients with known symptomatic brain metastases requiring steroids
  • Previous high-dose chemotherapy requiring stem cell rescue
  • Prior allogeneic stem cell transplant or organ graft
  • Any of the following within 6 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
  • Symptomatic pulmonary embolism within 6 months prior to study entry
  • Known HIV or AIDS-related illness
  • Active infection requiring systemic therapy
  • Positive HBV or HCV test indicating acute or chronic infection
  • Administration of a live vaccine within 4 weeks prior to study entry
  • Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ?6) prostate cancer
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
  • Persisting toxicity related to prior therapy >Grade 1
  • Other severe acute or chronic medical condition
  • Combo C :Existing periorbital edema.
  • Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture (within 12 weeks prior study entry)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Australia,   Canada,   France,   Japan,   Netherlands,   United Kingdom,   United States
 
 
NCT02554812
B9991004
2015-002552-27 ( EudraCT Number )
JAVELIN MEDLEY ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now